Skip to main content

Q-VANT supports the evolving needs of veterinary vaccine manufacturer.

Focusing on regional or local diseases and emergencies.
Developing affordable and safe adjuvants for farm and companion animal immunizations.
Veterinary quality and regulatory compliance requirements closely adhere to the requirements for human vaccines.
Providing a dossier for upgrading the source of saponin adjuvant in currently marketed vaccines and future developments.
Supporting procedures for quality and regulatory alignment across organizations.
Folha rural: Increasing the efficiency of beef cattle production within the concept of sustainability

Quality and Regulatory Requirements for Veterinary vaccines.

The European Union has provided additional guidance for veterinary vaccines, narrowing the regulatory gap with human vaccines, notably by identifying an adjuvant by the trade name and not the substance name. Certification of Good Manufacturing Practices is becoming more relevant. Veterinary Clinical trials may be registered in the USA, Canada, and EU.

Q-VANT recommends the use of highly purified and affordable saponin adjuvants for veterinary vaccines.

Strong potentiation of immune response. Increased production of antigen-specific antibodies and T-cell response.

Low cost in use due to low required dosage.

Q-VET S TM enhances the activation and antigen processing capacity of antigen presenting cells.

Q-VET S TM potentiates the antigen-specific antibody response better than Quil-A, the previous generation of saponin adjuvant.

Q-VET S TM enhances Both the cytotoxic T cell and T-helper cell response with a high IFN-gamma-secreting profile. Unlike Quil-A which only induces T helper cell response.

In swine model Q-VET S TM potentiates the production of antibodies with the same intensity as the first generation of saponin adjuvant.

Q-VET S offers the guarantee of a secure supply and volume for vaccines.

Q-VANT team can provide expertise on vaccine formulations with Q-VET S.